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The heart receives sympathetic and parasympathetic efferent innervation as well as the
ability to process information internally via an intrinsic cardiac autonomic nervous system
(ICANS). For over a century, the role of the parasympathetics via vagal acetylcholine release
was related to controlling primarily heart rate. Although in the late 1800s shown to play
a role in atrial arrhythmia, the myocardium took precedence from the mid-1950s until in
the last decade a resurgence of interest in the autonomics along with signaling cascades,
regulators, and ion channels. Originally ignored as being benign and thus untreated, recent
emphasis has focused on atrial arrhythmia as atrial fibrillation (AF) is the most common
arrhythmia seen by the general practitioner. It is now recognized to have significant mortal-
ity and morbidity due to resultant stroke and heart failure. With the aging population, there
will be an unprecedented increased burden on health care resources. Although it has been
known for more than half a century that cholinergic stimulation can initiate AF, the classical
concept focused on the M2 receptor and its signaling cascade including RGS4, as these
had been shown to have predominant effects on nodal function (heart rate and conduction
block) as well as contractility. However, recent evidence suggests that the M3 receptor may
also playa role in initiation and perpetuation of AF and thus RGS2, a putative regulator of the
M3 receptor, may be a target for therapeutic intervention. Mice lacking RGS2 (RGS2−/−),
were found to have significantly altered electrophysiological atrial responses and were
more susceptible to electrically induced AF. Vagally induced or programmed stimulation-
induced AF could be blocked by the selective M3R antagonist, darifenacin. These results
suggest a potential surgical target (ICANS) and pharmacological targets (M3R, RGS2) for
the management of AF.
Keywords: RGS proteins, autonomic nervous system, cholinergic, arrhythmia, atrial fibrillation, intrinsic cardiac
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INTRODUCTION
This “Special Topic” series explores how regulators of G protein
signaling (RGS) proteins share common, yet distinct roles at mul-
tiple levels, controlling autonomic regulation of heart function,
and what critical questions remain for translational researchers
examining the role of these pathways in conditions such as atrial
fibrillation (AF), where RGS proteins are currently being assessed
as potential druggable targets. Although cholinergic AF has been
investigated for decades, exact mechanisms are still controversial
(Schotten et al., 2011). AF is highly complex involving multi-
ple mechanisms for its initiation and sustaining the arrhythmia
including genetic contributions, structural, ion handling, and
autonomic alterations, the complexity of which results in beat-
to-beat, second-to-second, and having age-dependent substrate
changes. This paper provided some evidence on the role of RGS2
proteins in AF in the mouse. To put this into context, there is a brief
introduction of the role of autonomics in AF. For more complete
reviews, see a special review issue in Cardiovascular Research 2011
vol. 89 no. 4, and reviews by Dobrev and Nattel (2011), Schotten
et al. (2011), Wakili et al. (2011).
HISTORICAL CONCEPTS OF AUTONOMICS IN THE HEART
The heart receives both sympathetic and parasympathetic efferent
innervation as well as being able to process information via an
intrinsic cardiac autonomic nervous system (ICANS). The ICANS
may interact with the efferent nerve supply in a complex fashion
to regulate cardiac function and it is thought to act as a “mini-
brain on the heart.” The neurons of the ICANS are primarily
located in five groups of atrial ganglionated plexi (GPs) which
have been described by Arora et al. (2003) in the pig. These GPs
may represent areas of local control of cardiac muscle (Cardi-
nal et al., 2009). Although close proximity of the neurons to the
muscle does not mean exclusive control of the adjacent area, it is
an important consideration, and is analogous to the enteric ner-
vous system, which serves as the “local brain” in the intestinal
tract (Furness et al., 2004). Subpopulations of intrinsic cardiac
neurons express multiple neurotransmitters (Hassall and Burn-
stock, 1987); however, in Guinea pig posterior ganglia, choline
acetyltransferase immunostaining of all neurons indicates major
parasympathetic cholinergic input to the myocardium (Mawe
et al., 1996).
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ATRIAL FIBRILLATION
Atrial fibrillation, the most common clinical arrhythmia (Kan-
nel et al., 1982; Benjamin et al., 1998), is characterized by having
abnormal, irregularly irregular, rapid electrical activation. AF is a
common health problem in the developed world (Savelieva and
Camm, 2001). Its prevalence increases with age, from a preva-
lence of 0.02% of people of 18–39 years of age to 11.6% of people
over 75 years of age (Nixon, 2011). As the population ages, AF
will increase the burden on health care resources, both for its
therapeutic management, and also due to its serious and costly
complications: heart failure and stroke (Dries et al., 1998). Discus-
sion of potential mechanisms for AF, as far back as 1870 (Efimov
and Fedorov, 2005), has been separated into two basic themes;
those stressing the primary role of the ICANS (referred to as neu-
rogenic AF; Hoffa and Ludwig, 1850; Zipes et al., 1974; Coumel
et al., 1978; Liu and Nattel, 1997; Chang et al., 2001; Nattel, 2004),
or sometimes called “vagal AF” (Garrey, 1924) and those related
exclusively to the role of the atrial muscle itself (referred to as
myogenic AF). Both neurogenic (Hoffa and Ludwig, 1850; Zipes
et al., 1974; Coumel et al., 1978; Liu and Nattel, 1997; Chang et al.,
2001; Nattel, 2004) and myogenic (Vulpain, 1874; MacWilliam,
1887; Garrey, 1914; Moe and Abildskov, 1959; Moe, 1962; Moe
et al., 1964; Allessie et al., 1985; Zipes, 1997; Jalife et al., 1998;
Skanes et al., 1998; Mandapati et al., 2000) hypotheses have been
proposed to account for arrhythmia mechanisms. The separa-
tion of AF mechanisms into strictly neurogenic and myogenic
types is artificial as they certainly interact and share multiple
mechanisms.
Since the studies of Moe and colleagues in the 1950s, AF was
shown to be composed of multiple re-entrant wavelets (Nattel,
2002). However, optical mapping studies of AF in isolated sheep
atria have found that AF may involve both a high frequency
“mother rotor,” and fibrillatory conduction of multiple wavelets
spawned from the deterministic driver (Kleber, 2000; Jalife, 2003).
Remodeling of the atria may also promote the propagation of
multiple wavelets as “AF begets AF,” indicating that atrial remodel-
ing promotes sustained disorganized activity (Morillo et al., 1995;
Shen et al., 2011). AF relies on the interaction of triggers, perpet-
uators, and a vulnerable substrate for initiation and maintenance
of the arrhythmia (Allessie et al., 2001). Triggers combined with
dynamic substrates of structural heterogeneities, reduced refrac-
toriness, enhanced spatial dispersion of refractoriness and abnor-
mal impulse conduction initiate and perpetuate the arrhythmia
(Nattel et al., 2002). Focal activity originating from the pulmonary
veins has been suggested to account for more than 90% of AF
triggers (Haissaguerre et al., 2000).
Abnormal impulse initiation and conduction contribute to the
mechanism of AT (Figure 1), but are also involved in the initia-
tion and maintenance of AF. The rapid rates during AF (Nattel,
2002) promote remodeling of the atria that potentiates AF dura-
tion (AF begets AF). There are, however, a number of factors that
cause remodeling and “prime” the initial state, promoting rapid
triggers (e.g., pulmonary vein ectopy) and susceptibility to fibril-
latory conduction necessary for AF. These “clinical risk factors”
(Rosiak et al., 2010) for the onset and development of AF are
listed in Figure 2, for more detail see Dobrev and Nattel (2011).
Two factors not mentioned in the Rosiak article are mechanical
FIGURE 1 |The leading circle, “wave length,” of re-entry in atrial
fibrillation (AF). The size of a functional re-entry circuit [(A), right], depends
on the wavelength (WL) which is a product of conduction velocity (CV) and
refractory period (RP; WL=CV×RP). Short wavelengths allow multiple
circuits [(B), left], favoring AF. The wave rotating around a fixed point, rotor
[(C), lower; Jalife, 2003]. Factors such which slow conduction enhance the
potential for multiple smaller waves. Enhanced cholinergics decrease
conduction velocity and/or reduce effective refractoriness. Modified
connexins also slow conduction. Either, or a combination of both could
promote the initiation and sustaining of AF.
stretch and hyperthyroidism (Klein and Ojamaa, 2001; Souza et al.,
2012). Although usually associated with other contributing factors
such as hypertension or valve disease, stretch and stretch-induced
channel conduction can lead to electrical instability. Indeed, inter-
actions between mechanical stretch and cholinergic stimulation
has been shown (Yamazaki et al., 2009). Although in embryonic
and not the adult atria, there is evidence of interaction between M3
receptors and TREK-2, a stretch activated K+ channel (Kang et al.,
2006). There are also interactions between mechanical stretch and
gap junctions (Wang et al., 2000). These interactions can be very
complex. For instance, Cx40−/− mice had a lower pacing induced
breakdown frequency of 1–1 right atrial impulse conduction than
wild type mice but did not present with AF (Bagwe et al., 2005).
This indicates that the factors that promote fibrillatory conduc-
tion may not necessarily contribute to the mechanism driving AF
and may even oppose it. On the other hand, slowed conduction
in patients with somatic connexin 40 (Gollob et al., 2006) or con-
nexin 43 mutations (Thibodeau et al., 2010) or mice with mutant
connexin 43 (Tuomi et al., 2011) were associated with enhanced
arrhythmia susceptibility.
Atrial fibrillation causes remodeling of the atria that promotes
long lasting or even permanent AF (Thijssen et al., 2000). AF
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FIGURE 2 | A model of factors involved in arrhythmogenesis and the
effect of remodeling with the classical and more recent factors
thought to be involved in arrhythmia risk.
can be classified based on its duration and therapeutic history
(Nixon, 2011; Yan and Kowey, 2011). Patterns of AF follow-
ing the ACC/AHA/ESC guidelines include: (1) Paroxysmal (self-
terminating), episodes that generally last less than or equal to
7 days (most less than 24 h); (2) Persistent (not self-terminating),
usually more than 7 days, and (3) Permanent, cardioversion failed
or not attempted. Either paroxysmal or persistent AF may be
recurrent (Fuster et al., 2001).
Persistent AF is associated with diffuse macroscopic and histo-
logical atrial myocardial changes, i.e., remodeling. Atrial arrhyth-
mia can also cause ventricular remodeling and, if protracted,
cardiac failure. This in turn, can feed back on the atria and produce
irreversible interstitial atrial fibrosis (Kalifa et al., 2003).
Lone or paroxysmal AF has been shown to be primarily ini-
tiated from the pulmonary veins and posterior left atrial regions
(Morillo et al., 1995; Haissaguerre et al., 1998), where most of
the GP are in contact with the left atrium. Both alterations in
vagal responses and a significant increase in AF control (Pappone
et al., 2000, 2004; Nademanee et al., 2004; Platt et al., 2004; Nak-
agawa et al., 2005a,b) were found in patients when the GPs were
targeted (Sakamoto et al., 2010) or inadvertently modified dur-
ing catheter ablation of AF sources in the pulmonary veins. Also,
selective ablation of the GPs in pigs abolished the ability to acutely
induce AF (Jones et al., 2008b) and reduced the acute inducibility
in dogs (Nishida et al., 2011), which persisted in some animals
up to 4 weeks following ablation in dogs (Nishida et al., 2011).
These observations demonstrate the importance of the ICANS in
AF, i.e., neurogenic AF (Hoffa and Ludwig, 1850; Zipes et al., 1974;
Coumel et al., 1978; Liu and Nattel, 1997; Chang et al., 2001; Nat-
tel, 2004). Neurogenic or sometimes called “vagal AF” (Garrey,
1924) relies extensively on the action of acetylcholine. The roles
of acetylcholine in setting the stage for rotor development and
stabilization of the leading sources of AF have been reviewed (Sar-
mast et al., 2003; Efimov and Fedorov, 2005; Dobrev and Nattel,
2011; Schotten et al., 2011; Wakili et al., 2011). Acetylcholine pro-
motes left to right frequency gradients and enhances the dominant
frequency of the AF driver (Mansour et al., 2001). These responses
were also dependent on acetylcholine concentration, with higher
concentrations resulting in faster dominant frequencies. Previous
studies on AF mechanisms commonly focus on dependence on
acetylcholine concentration and the expression profiles of recep-
tors and downstream effectors, while ignoring the regulators of
the G protein signaling cascades.
ATRIAL MUSCARINIC ACETYLCHOLINE RECEPTORS
Five different subtypes of muscarinic acetylcholine receptors have
been cloned. M1, M3, and M5 receptors are Gαq coupled recep-
tors, while M2 and M4 receptors are Gαi/o coupled. The classical
notion is that the cardiac muscarinic acetylcholine receptors are
exclusively of the M2 subtype as M2 receptors are the most plenti-
ful. However, there is increasing evidence supporting an important
functional role of M3 receptors (Shi et al., 2004; Wang et al., 2004).
Of interest, even in the recent review (Schotten et al., 2011), dif-
ferential effects of cholinergic stimulation, despite its presence in
the heart, overlook M3 and are solely related to M2-cholinergic
innervation using archival information based on vagal stimula-
tion and atropine blockade “. . . heterogeneity in the distribution
of. . .M2-cholinoceptors (4, 343).”Reference 4 is Alessi et al. (1958).
Reference 343 is Liu and Nattel (1997). Both of these references
are prior to the description of M3 receptors in the heart. More
recently however, novel M2 blockade with NTC-801 was found
to block experimental AF, although its effects on M3 receptors
were not assessed (Machida et al., 2011). M3 muscarinic recep-
tors were first identified in human atria in Hellgren et al. (2000).
Early quantification of M1–M5 muscarinic subtype mRNAs in
rat atria utilizing competitive RT-PCR indicated that M2 mRNA
represented more than 90% of the total muscarinic mRNA in the
atria, while M3 was less than 3% (Krejci and Tucek, 2002). More
recently, quantitative PCR showed low level expression of M1, M4,
and M5 receptors in the atria, but this may have been due to low
level DNA contamination as RNA in most studies was not treated
with DNAse (Kitazawa et al., 2009). The functional consequence
of co-expression of multiple muscarinic receptor types has been
the focus of many studies discussed below, the most compelling of
which use M2 and M3 receptor knockout mice.
After 1 week of rapid pacing, Yeh et al. (2007) found approxi-
mately a 50% decrease in levels of mRNA encoding M2, M3, and
M4 receptor subtypes in both the left atrial appendix and left pul-
monary vein region. In contrast, Voigt et al. (2010) found there
were differential alterations in samples from atrial appendices of
patients with chronic or paroxysmal AF. In paroxysmal AF, basal
current was ∼2-fold larger in the left versus right atrial appen-
dix, indicating a left-to-right atrial gradient. In both atria, Kir2.1
(IK1) expression was ∼2-fold greater in chronic AF but compa-
rable in paroxysmal AF versus patients in sinus rhythm. Kir2.3
levels (IK, ACh) were unchanged in chronic AF and the right atrial
appendix in paroxysmal AF but were 51% lower in the left atrial
appendix in paroxysmal AF. In sinus rhythm carbachol-activated
IK, ACh was 70% greater in RA versus LA. This right-to-left atrial
gradient was decreased in paroxysmal and chronic AF caused by
a selective reduction in IK, ACh in right atrium. Similarly, in sinus
rhythm, Kir3.1 and Kir3.4 proteins were greater in right versus
left atrium and decreased in the right atrium of paroxysmal and
chronic AF. Kir3.1 and Kir3.4 expression was unchanged in the left
atrium of paroxysmal and chronic AF (Voigt et al., 2010).
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In the heart, M2 receptors inhibit adenylyl cyclase (AC) activ-
ity via Gαi and induce activation of the G protein coupled inward
rectifier K+ channel (GIRK3.1/3.4 or IK, ACh; Kovoor et al., 2001) by
Gβγ released from Gαi. Inhibition of adenylyl cyclase production
of cAMP reduces the activity of I f (a cAMP dependent current)
and the L-type Ca2+ current (ICa, L) through Gαo. ICa, L is also
regulated by Gαi and nitric oxide (Burger et al., 2009a,b). Adenylyl
cyclase 5 deficient mice have reduced ICa, L activity, while Gαi2
knockout mice lack muscarinic regulation of ICa, L (Chen et al.,
2001). M2 receptor inhibition of Gαi decreases cAMP produc-
tion, which reduces protein kinase A (PKA) activation (Kovoor
et al., 2001). PKA, through phosphorylation, increases the activ-
ity of ICa, L and the rapid delayed rectifier potassium channel
(IKr), which promotes repolarization from the plateau phase of
cardiac action potential (Tamargo et al., 2004). The inhibition of
IKr prolongs AP duration (Clark et al., 2004).
In the atria, activation of IK, ACh increases membrane K
+ per-
meability, facilitating an outward current that hyperpolarizes the
cell. There is a gradient of IK, ACh current in the mouse atria that,
when combined with the heterogeneous distribution of parasym-
pathetic ganglia, may augment the dispersion of atrial refractori-
ness (Lomax et al., 2003). In mice (Nygren et al., 2004), optically
mapped action potential duration was shorter in the left than
the right atrium (Nygren et al., 2004) and the cholinergic ago-
nist, carbachol, reduced durations in all areas except the left atrial
appendage. GIRK4 knock out (GIRK4−/−) mice which lack func-
tional IK, ACh channels have abnormal heart rate regulation and
are resistant to carbachol-induced AF (Kovoor et al., 2001). In
the SA node, IK, ACh hyperpolarizes the membrane potential, and
decreases the pacemaker pre-potential slope, which contributes
∼50% to the in vivo bradycardic response. In summary, the
functions of the M2 receptor include activation of IK, ACh (hyper-
polarization), inhibition of IKr (prolonging repolarization), and
inhibition of I f (negative chronotropy; Hashimoto et al., 2006).
On the other hand, M3 muscarinic receptors couple to Gαq to
activate PLC, PKC, and IK, M3 (Shi et al., 2004). To date, IK, M3 is
the only identified K+ channel activated by Gαq. IK, M3 current
is highly selective for K+ and has delayed rectifier properties with
a relatively slow activation time constant (∼150 ms at +50 mV),
which is followed by a partial and slower decay (Wang et al., 2004).
The tail current is characterized by an initial rapid rising phase fol-
lowed by a slow decay with a mean time constant of ∼170 ms (Shi
et al., 2003). The waveform is similar to that of IKr; however, it
is insensitive to the IKr blockers dofetilide and E-4031, and to
the slow delayed rectifier K+ current (IKs) inhibitor, chromanol
293B. IK, M3 is blocked by the non-selective muscarinic antago-
nist, atropine (Wang et al., 2004), and the M3 selective antagonist,
darifenacin (Wang et al., 2004, 2007a). M3 content is also altered
in patients with chronic AF associated with mitral stenosis (Zhao
et al., 2008) and in experimental chronic tachycardia in dogs (Yeh
et al., 2007).
Of note, M3 receptor distribution in cardiac tissue was found
to be mostly confined to the intercalated disk region (Wang et al.,
2004), and thus was also suggested to regulate ventricular gap
junction-mediated cell-to-cell conduction (Wang et al., 2007a).
Physical and functional interactions between M3 and connexin
43 (Cx43) have been found in rat ventricular myocytes, which
were impaired during myocardial ischemia (Yue et al., 2006). Gap
junction remodeling is an essential component promoting atrial as
well as lethal ventricular tachyarrhythmias (Dupont et al., 2001a,b;
Gutstein et al., 2001; Danik et al., 2004; Shiroshita-Takeshita et al.,
2007). The functions of the cardiac M3 receptors suggested so far
include: (1) depressed inotropy; (2) protection against myocar-
dial ischemia; (3) regulation of cell-to-cell communication, and
(4) participation in the generation and maintenance of AF (Wang
et al., 2004). Using the M3 receptor antagonist 4-DAMP Wang
et al. (2004), concluded that the M3 receptor also mediates, in
part, bradycardia elicited by vagal stimulation. However, the pKb
of 4-DAMP for M3 is 8.9–9.3, only one order of magnitude greater
the pKb for M2 receptors (7.8–8.4). Perhaps the weak inhibition
of vagal bradycardia with high dose 4-DAMP used in Wang’s study
was due to blockade of M2 rather than M3 receptors. On the other
hand, vagally induced bradycardia was completely abolished in M2
muscarinic receptor (M2−/−) deficient mice but was not affected
in M3 muscarinic receptor (M3−/−) deficient mice (Fisher et al.,
2004), which does not support a role for M3 in bradycardia in the
mouse. However, this does not exclude a role for M3-mediated
modulation of atrial or AVN function, as analysis of other atrial
or AVN functions was not done.
The functional consequence of co-expression of both M2
and M3 receptors in the atria was studied in M2−/−, M3−/−,
and M2/M3 double knockout (M2−/−/M3−/−) mice (Kitazawa
et al., 2009). In wild type mouse atria, carbachol-induced a
negative inotropic response followed by a sustained positive
inotropic response. M3−/− mice were devoid of the positive
inotropic phase while M2−/− mice had only a positive inotropic
response. M2−/−/M3−/− double knockout mice were devoid of
any inotropic response (Kitazawa et al., 2009). The susceptibil-
ity to arrhythmia was not studied in these mice. However, these
results strongly indicate the functional nature of M3 muscarinic
receptors present in the atria.
G PROTEIN COUPLED RECEPTORS IN THE HEART
G protein coupled receptors (GPCRs) are seven transmembrane
domain cell surface receptors that bind extracellular ligands (hor-
mones, neurotransmitters, and drugs) and transduce signals into
the intracellular environment. Most sympathetic and parasym-
pathetic receptors are members of the GPCR superfamily which
couple to various downstream signaling cascades including those
controlling adenylyl cyclase, Ca2+ homeostasis, and ion chan-
nels (Wieland et al., 2007). In the heart, GPCRs control the
chronotropic (rate of contraction), inotropic (strength of contrac-
tion), lusitropic (rate of relaxation), and dromotropic (velocity of
conduction) responses to acetylcholine and adrenaline (Wieland
et al., 2007). Ligand binding stabilizes or induces a conforma-
tional change in its GPCR that activates a coupled intracellular
heterotrimeric G protein (Gαβγ). There are four families of mam-
malian heterotrimeric G proteins including Gsα, Gi/oα, Gqα, and
G12/13α with various subtypes, effectors, and expression profiles
(Milligan and Kostenis, 2006).
RGS2 AND RGS4 IN THE HEART
Regulators of G Protein Signaling proteins were first identified
as GTPase activating proteins (GAPs), accelerating the intrinsic
Frontiers in Physiology | Cardiac Electrophysiology June 2012 | Volume 3 | Article 239 | 4
Jones et al. Autonomics and cardiac arrhythmia
GTPase activity of Gα subunits, as the duration of G protein activa-
tion is primarily controlled by GTP hydrolysis. Also, RGS proteins
can interfere with G protein binding to effector proteins, sepa-
rate from their regulation of hydrolysis (Abramow-Newerly et al.,
2006). Thus RGS proteins are important limiters of GPCR sig-
naling. Currently, 20 different genes encoding RGS proteins have
been identified and divided into four subfamilies, based on their
sequence and structural similarities: RZ/A (RGS17, 19, and 20);
R4/B (RGS1–5, 8, 13, 16, and 21); R7/C (RGS6, 7, 9, and 11), and
R12/D (RGS10, 12, and 14; Bansal et al., 2007). The majority of
RGS proteins are GAPs for Gαi/o and many also act on Gαq/1189;
however, none are GAPs for Gαs but some RGS-like proteins such
as p115RhoGEF do have GAP activity on the Gα11/12 subfam-
ily. RGS2, 3, 4, 6, 10, RGSZ2, and GAIP are all found in atrial
cardiomyocytes (Doupnik et al., 2001).
The ongoing control of cardiac function by GPCRs is itself
modulated by RGS proteins. RGS-insensitive GαoG184S homozy-
gous knock-in (Gαi2GS/GS) embryonic stem cell-derived car-
diocytes had enhanced responses to M2 muscarinic but not A1
adenosine receptor stimulation, while analogous GαoGS/GS car-
diocytes had enhanced A1 adenosine and M2 receptor mediated
responses (Fu et al., 2006). Gαs stimulation of the intrinsic beating
rate was almost completely abolished in Gαi2GS/GS cells, likely
due to a failure of AC activation resulting from an increase in
countervailing inhibitory activity. Gαi2GS/GS insensitive mutant
mice also had pronounced (five-fold greater) muscarinic medi-
ated bradycardia and third degree AV nodal block (Fu et al., 2007).
These mutant mouse data indicate that in the SA and AV node,
M2 receptors primarily couple through Gαi2 to inhibit cAMP pro-
duction and activation of PKA (Fu et al., 2006, 2007). Adenosine
1 and 3 receptor overexpressing mice have also have prolonged
AVN conduction (Kirchhof et al., 2003; Fabritz et al., 2004), which
may involve receptor mediated inhibition of adenylyl cyclase 5/6
(AC5/6), primarily coupling through Gαo (Fu et al., 2006, 2007).
Susceptibility to atrial arrhythmia has not been examined in these
mice. It is currently believed that specific RGS proteins may couple
to specific signaling pathways within the cell.
RGS2, a member of the R4/B subfamily, the second most highly
expressed RGS protein in the heart (Doupnik et al., 2001), is a selec-
tive GAP for Gαq (Zou et al., 2006). This selectivity does not reflect
any exceptional affinity for the latter but rather a relatively weak
RGS2 affinity for Gαi/o (Ingi et al., 1998; Cladman and Chidiac,
2002) which is due to the substitution of three conserved amino
acid residues in its RGS domain that decrease binding affinity to
Gαi/o but not Gαq (Heximer et al., 1999). RGS2 also produces
a poorly understood inhibitory effect on Gs-activated AC signal-
ing (Sinnarajah et al., 2001; Roy et al., 2006b). The mechanism by
which such inhibition occurs does not appear to involve a GAP
effect, as RGS2 fails to alter the GTPase activity of either free (Ingi
et al., 1998) or receptor-activated Gs (Roy et al., 2003). Some evi-
dence suggests that the inhibitory effect may involve a physical
interaction of the N-terminus of RGS2 with the C1 catalytic loop
of AC5 (Salim et al., 2003; Beazely and Watts, 2006); however other
studies suggest that RGS2 may bind directly to Gαs (Tseng and
Zhang, 1998; Ko et al., 2001). In HEK293 cells, GFP-RGS2 tended
to localize to the nucleus but was recruited to the plasma mem-
brane by the co-expression of either Gαs or most adenylyl cyclase
isoforms, and BRET (bioluminescence resonance energy transfer)
interactions between RGS2 and Gαs are not inhibited by adenylyl
cyclase (Roy et al., 2006a). RGS2 appears to be important in the
desensitization of Gq- and Gs-mediated GPCR receptor signals
as it is upregulated by both and moreover it can mediate cross-
desensitization between Gαq and Gαs (Sinnarajah et al., 2001; Roy
et al., 2006b).
Removal of RGS2’s inhibitory effect on Gαq signaling increases
Gαq-dependent signaling activity in cardiomyocytes (Zhang et al.,
2006). Interestingly, RGS2 has also been shown to be an impor-
tant target in cardiovascular disease (cardiac hypertrophy and
hypertension; Tsang et al., 2010). RGS2−/− mice have a mild to
moderate hypertensive phenotype (Heximer et al., 2003; Gross
et al., 2005; Tank et al., 2007) that is suggested to be mediated
by vascular changes, possibly through angiotensin II, endothelin
and/or α-adrenergic receptors, rather than being due to cardiac
alterations, although cardiac “contractility,” measured by left ven-
tricular dP/dt, was not determined (Oliveira-dos-Santos et al.,
2000; Heximer et al., 2003). Altered autonomic function and
effects mediated via the kidneys may also contribute to elevated
blood pressure in these animals (Gu et al., 2009). An increase in
mean arterial pressure of ∼10 mm Hg was found with Teleme-
try, while heart rate was unchanged, indicating a resetting of
the baroreceptor reflex (Gross et al., 2005). This was confirmed
by directly measuring baroreflex sensitivity calculated by cross-
spectral analysis of heart rate variability. However, heart rate
variability was not different in RGS2−/− compared to RGS2+/+
mice (Gross et al., 2005), indicating that the cardiac phenotype
was not explained by a baroreflex mediated enhancement of vagal
nerve activity. Since RGS2 is a selective regulator of Gαq sig-
naling that can inhibit signaling via M3 receptors in other cell
types (Tovey and Willars, 2004; Karakoula et al., 2008), it follows
that RGS2 may be an important regulator of M3 muscarinic sig-
naling in the atria. Notably, the scaffolding protein spinophilin,
which is present in cardiomyocytes (Bers, 2004), binds to both
RGS2 and M3 muscarinic receptors, and thus it may facilitate the
inhibition of M3 muscarinic receptor-activated Gq signals, as has
been observed with analogous α1-adrenergic signals (Wang et al.,
2007b).
RGS4 regulates SA nodal function (Cifelli et al., 2008) via
inhibition of parasympathetic signaling and IK, ACh activity. In
mice expressing LacZ under the control of the RGS4 promoter,
high expression of LacZ-RGS4 was found in the SAN will little
expression was observed in the surrounding right atrium. RGS4-
null (RGS4−/− mice had lower baseline heart rates and greater
increases in heart rate following atropine blockade. High expres-
sion of RGS4 (demonstrated by LacZ staining), was also seen
in the AV node and RGS4−/− mice were highly susceptible to
carbachol-induced AV nodal conduction block when treated with
isoproterenol. However, there is limited electrophysiological data
describing the location of conduction block, and results were
obtained principally in Langendorff hearts (removed from in vivo
autonomic influences).
As RGS4 was found only in the SA and AV nodal region, the RGS
protein regulating parasympathetic signaling and IK, ACh activity
in the atrium remained, until recently, unknown. RGS6-deficient
(RGS6−/−) atrial myocytes exhibited a significant reduction in
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the time course of IK, ACh activation and deactivation. RGS6
−/−
mice also displayed bradycardia and AV nodal conduction block
indicating that there is at least partial redundancy in RGS protein
function in vivo.
RGS2 AND ATRIAL ARRHYTHMIA IN THE MOUSE
In both RGS2−/− and C57Bl\6 wild type (WT, control) anes-
thetized mice (Tuomi et al., 2010) with body temperature main-
tained within the normal physiological range (36.5–38˚C; Con-
nolly and Lynch, 1981) and His bundle recording (Figure 3) used
to validate correct positioning of the electrode (Figure 4), atrial
effective refractory periods (AERPs) were heterogeneous, being
longer in the high right compared to the mid right atrium. In addi-
tion, AERPs were significantly lower in RGS2−/− mice compared
to WT mice. M2 receptor and M3 receptor mRNA was not different
in RGS2−/− compared to WT mice. Carbachol reduced AERPs in
both strains but strain differences persisted. In contrast, the AERPs
were increased to similar levels in both strains with atropine.
The selective M3 blocker, darifenacin, increased the AERP for
the mid atrium of RGS2−/− and WT mice, and eliminated the
strain-related differences (Tuomi et al., 2010), supporting a role
FIGURE 3 | A photograph of an octapolar electrode catheter (CIB’ER
Mouse®, NuMED, Inc., Hopkinton, NY, USA) used for recording from
the atrium, His bundle region and ventricle of the anesthetized mouse.
The small marks on the ruler are 1 mm spacing.
of RGS2 in atrial function. Of interest, in paroxysmal AF there
is a frequency gradient but in chronic AF, the frequency gradi-
ent in the left atrium has been shown to be absent (Lazar et al.,
2006).
Since vagally induced bradycardia is mediated via M2 but not
M3 receptors (Fisher et al., 2004), we compared the effects of
cholinergic blockade using darifenacin and atropine on heart rate
changes following vagus nerve stimulation. Stimulating the vagus
decreased heart rate by 38± 6.8% in WT animals. This decrease
was abolished by atropine but was unaltered in the presence of
darifenacin (Tuomi et al., 2010). This provided evidence that this
dose of darifenacin did not affect M2 signaling. Of note, this dose
of darifenacin also terminated electrically induced fibrillation in
connexin 43 mutant mice (Tuomi et al., 2011).
Both programmed electrical stimulation (Jones et al., 2001)
and burst pacing (Jones et al., 2008a) were used to determine sus-
ceptibility to atrial arrhythmia induction. A single atrial stimulus
induced AF (Figure 5). Overall, RGS2−/− mice were more sus-
ceptible to electrically induced arrhythmia (Table 1; Tuomi et al.,
2010).
Atrial fibrillation is very rarely induced by single extrastim-
uli in large animal and human studies and was thus anticipated
to be even less provocable in mice, due to their small size. Thus
sensitivity to single extrastimuli in the mouse implies a highly
vulnerable myocardial substrate. The duration of induced arrhyth-
mia is also important with “sustained” AF being defined in large
animal and human electrophysiological studies as lasting >30 s.
Scaling of electrophysiological variables has been related to the
BM0.25 (Noujaim et al., 2004). Using this relationship, the dura-
tion equivalent is in the second range. However as there is no gold
standard: indeed not even a convention, we concluded it best to
use ranges. Hence, the data were analyzed based on susceptibility
to pacing modality and grouped by the duration of the induced
arrhythmia, lasting: <10 s; between 10 and 30 s, and >30 s. As
expected, WT mice were virtually non-inducible with a single
FIGURE 4 | ComputedTomography (CT) of the catheter position in
the right heart of the anesthetized mouse. The mouse’s head is at
the top and tail, off the bottom of each image. (A) The white bracket
delineates the region of interference from catheter’s eight electrodes
shown as very bright echoes extending laterally from the catheter. (B)
A sagittal view of the digitally inserted catheter. The white bracket
delineates the position of the catheter’s eight electrodes. The bright
dots to the left of the torso are from the ribs and those on the left are
from the spinal column. (C) A coronal view of catheter placement with
electrodes three and four across the tricuspid valve. The white bracket
delineates the catheter’s eight electrodes. The bright dots to the left
and right of the torso are from the ribs.
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FIGURE 5 | Programmed electrical stimulation-induced atrial fibrillation
(AF) in a 1-month-old RGS2−/−mouse (A). Note the conduction block into
the high right atrial (HRA) region denoted by the far-field (low amplitude)
potential recordings during block. The duration of the arrhythmia was >200 s
with an average atrial rate of ∼1600 bpm. A similar stimulation protocol failed
to induce atrial fibrillation in wild type mice (B). LL1, limb lead 1.RV, right
ventricular electrogram. HBE, electrogram from the His bundle region. HRA,
recording from the high right atrium.
stimulus (4%, 1/25), compared to burst pacing (40%, 10/25).
Carbachol increased the susceptibility to both single extrastim-
uli (33%, 4/12) and burst pacing (58%, 7/12). Carbachol also
prolonged the fibrillation duration with only 2 of 12 untreated
mice being sustained, while 5 of the 12 were sustained after
carbachol. The atrial stimulation site also affected arrhythmia
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Table 1 | Incidence of AT/F induced by PES or burst pacing and
maximum duration of induced AT/F with either PES or burst pacing
induction.
Wild type RGS2−/−
INDUCIBILITY
PES 4% (1/25) 50% (11/22)
Burst (50 Hz, 400 ms pulse) 40% (10/25) 64% (14/22)
DURATION
No response 60% (15/25) 36% (8/22)
<10 s 20% (5/25) 23% (5/22)
10–30 s 16% (4/25) 18% (4/22)
>30 s 4% (1/25) 23% (5/22)
X2 analysis of discrete values revealed significant differences in atrial tachycar-
dia/fibrillation (AT/F) susceptibility with programmed electrical stimulation (PES;
P< 0.05).
susceptibility. Burst pacing more readily induced arrhythmia from
the mid right atrium of WT mice (40%, 10/25) compared to those
from the high right atrial region (8%, 2/25, P < 0.05; Tuomi et al.,
2010). This likely reflects the regional AERPs being significantly
shorter in the mid-compared to the high right atrium. Electrical
heterogeneity may be an important factor in providing a per-
missive substrate for wave break and re-entry initiation in the
atrium.
Rapid focal activity may initiate rotors due to the interaction
of a high frequency propagating wave fronts with the refrac-
tory tail of the previous wave (Jalife and Pandit, 2005; Vaquero
et al., 2008). Immediately after arrhythmia induction, local cycle
lengths were often identical in the high right and His bundle
regions. However, sometimes at onset, there was regional conduc-
tion block into the high right atrium (Figure 5), which could be
accompanied by heterogeneity in local cycle lengths in RGS2−/−
mice, with His bundle electrograms being shorter than those
of the high right atrium. Over time, these intervals converged
(Tuomi et al., 2010). This pattern is consistent with the con-
cept of a drifting rotor that rapidly became anchored, although
it may also indicate a tachycardia with a rapid rate at onset that
slowed down as the driving mechanism stabilized. However, rapid
onset may combine with the regional refractory heterogeneity
to produce functional conduction block/slowing that eventually
recovers at slower rates. Of note, the cycle length during arrhyth-
mia was faster than the measured intrinsic AERP in the high right
atrial region, suggesting the possibility of electronic interactions
from a rotor core causing reduced refractoriness (Vaquero et al.,
2008).
In summary, in addition to the previous focus on the role of
M2 receptors in atrial arrhythmia, there is evidence that arrhyth-
mia inducibility may be due to parasympathetic M3 receptors and
their regulation by RGS2 knockout. RGS2 accelerates the intrinsic
GTPase activity of Gαq, thus limiting the lifetime of the activated
state, thereby regulating the Gαq coupled M3 receptor and its
associated current, IK, M3. These data are the first we know that
demonstrate a role for RGS proteins in atrial arrhythmia. The
RGS2−/− mice were more susceptible to electrically induced AF,
and there was a greater percentage of RGS2−/− mice with sus-
tained AF. This strain dependent difference was maintained in
the presence of carbachol, while atropine abolished the strain
dependent differences. These findings suggest an alteration in
muscarinic receptor-gated K+ flux evidently due to an increase
in M3 muscarinic receptor response per se.
CONCLUSION
With the aging of the population, there is an increasing drive
to identify novel treatments for AF. This will require increased
understanding of the signaling pathways and molecular regula-
tors involved in arrhythmia induction, perpetuation, and atrial
remodeling. Current medical management of cardiac arrhyth-
mias depends primarily on ion channel blockade, most of which
(∼70%) are controlled by GPCRs; however, these agents may
be proarrhythmic (The Cardiac Arrhythmia Suppression Trial
(CAST) Investigators, 1989) and reduce the quality of life of the
patients. Thus developing selective agents for cholinergic signaling
may provide an effective treatment for AF initiation and perpetu-
ation. Mutations in, or altered expression/function of a variety of
RGS proteins could be involved in AF mechanisms in patients,
and indeed, changes in RGS2 have been identified in several
human cardiovascular phenotypes. Thus, targeting RGS proteins
may be important for drug development (Roman et al., 2009).
Selective M3R blockade, alone, or in combination with other anti-
arrhythmic agents, may be useful for patients with AF. However,
in mice, oral darifenacin exerted only transient binding to cardiac
muscarinic receptors (Yamada et al., 2006), thus its use may be
limited.
LIMITATIONS
While these results indicate a role for RGS2 and the M3 mus-
carinic receptor in promoting AF in the mouse, additional studies
will need to directly determine the role of IK, M3 activity. Also, it
would be beneficial to examine the effects of novel IK, ACh antago-
nists NTC-801 (Machida et al., 2011) and IKur antagonist, acacetin
(Li et al., 2008). Atrial vulnerability may also be due to a balance
of autonomics (Scherlag et al., 2006; Jones et al., 2007). RGS2−/−
mice have also been shown to have reduced renal sympathetic
nerve activity compared to WT mice (Tank et al., 2007). Although,
the lack of a heart rate difference between RGS2−/− and WT mice
found in their earlier study (Gross et al., 2005) does not assist in
establishing the role of the sympathetic nervous system in atrial
susceptibility, the role of the balance between sympathetics and
M3 responses remains to be determined. It is also recognized
that it may not be possible to directly extrapolate from mouse
experiments to the human.
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